Phase 2 N=39 Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma · Recurrent Skin Squamous Cell Carcinoma
Primary: Overall Response Rate — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
Non-alcoholic Fatty Liver Disease
Primary: Plasma Amine Oxidase Copper-containing 3 (AOC3) Activity After 12 Weeks of Treatment, Relative to Baseline in Percent — 102; 24.0; 13.1; 8.27 Percentage relative to…
Phase 2 N=20 Effect of Secretin in Functional Dyspepsia and Healthy Subjects
Dyspepsia · Healthy
Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12
Phase 2 N=20 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Phase 2 N=8 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Behcet Disease
Primary: Number of Participants With Attacks — 0 Participants
Phase 2 N=36 GSK2982772 Study in Subjects With Ulcerative Colitis
Colitis, Ulcerative
Primary: Part A: Number of Participants With Common (>=5%) Non-serious Adverse Events (Non-SAEs) and Any Serious Adverse Events (SAEs) — 7; 13; 1; 0 Participants
Phase 2 N=57 Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations
Tympanic Membrane Perforation
Primary: Number of Patients With Tympanic Membrane Closure Following Treatment — 23; 10 Participants
Phase 2 N=19 A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Pulmonary Arterial Hypertension
Primary: Maximum Tolerated Dose (MTD) of BPS-MR in Pulmonary Arterial Hypertension (PAH) Patients, Following Chronic, Twice-daily Administration. — 2; 2; 3; 2 Participants
Phase 2 N=301 Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Numeric Rating Scale (NRS) Average Pain Intensity — -1.50; -1.61; -1.15; -1.23 score on a scale
Phase 2 N=241 A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Endometrial Neoplasms
Primary: Progression Free Survival (PFS) — 3.7; 5.6; 2.1; 2.0 months — p==0.178
Phase 2 N=42 Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia With Multilineage Dysplasia
Primary: Complete Remission Rate (CR) — 20 Participants
Phase 2 N=301 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants With Antibody Titers ≥1:4 and ≥1:8 Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C…
Phase 2 N=305 BARDA Securing Anthrax Immunity For the Elderly
Anthrax
Primary: Solicited Local Reactogenicity Symptoms — 46; 43; 40; 45 Participants
Phase 2 N=1,715 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y…
Phase 2 N=56 Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Sarcoma, Soft Tissue · Soft Tissue Sarcoma
Primary: Clinical Benefit Rate — 22 Participants